Wholesaler AmerisourceBergen and competitor McKesson report earnings; Merck expands work with Synthace;

> London-based Synthace said it has expanded an agreement to work with Merck & Co. ($MRK) on processes to use Synthace's bioprocesses and computer language Antha on a biomanufacturing platform for a number of undisclosed Merck molecules. Release

> Drug wholesaler AmerisourceBergen ($ABC) reported adjusted earnings of $1.17 per share for its fourth quarter, missing Wall Street projections of $1.18 per share. Report

> Drug wholesaling and services company McKesson ($MCK) reported adjusted earnings of $3.31 per share, well above analyst expectations of $2.97 per share. Report

Suggested Articles

The eight-year deal will initially cover lupus drug Benlysta and could expand to other GSK specialty-care products in the future.

With a new £131 million contribution from the U.K. government, VMIC aims to both speed up and expand on its prior ambitions.

Pricing controversies shouldn't overshadow Phlow's promise to provide low-cost drugs to address COVID-19, says the CEO of partner Civica Rx.